Short- and Mid-Term Follow-Up Results after Percutaneous Transvenous Mitral Commissurotomy.

Takarada, Akira; Kohno, Hiroyuki; Hayashi, Takatoshi; Itoh, Shigeki; Mori, Takao; Fujimoto, Toshinori; Yasaka, Yoshinori; Itagaki, Takeshi; Nakayama, Ichirou; Teragawa, Hiroki; Shimatani, Yuhji; Yoshida, Yutaka

doi:10.1536/ihj.33.771

Cited by 5 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significant reduction of LA size following successful mitral valvotomy was demonstrated by several investigators [39][40][41][42]. To demonstrate the effect of PMBV on left atrial size, 205 consecutive patients (mean age 31 6 11 years) were studied by the author [42].…”

Section: Effect Of Pmbv On Left Atrial Sizementioning

confidence: 99%

Percutaneous mitral balloon valvotomy

Fawzy

2007

Cathet Cardio Intervent

View full text Add to dashboard Cite

Percutaneous mitral balloon valvotomy (PMBV) was introduced in 1984 by Inoue who developed the procedure as a logical extension of surgical closed commissurotomy. Since then, PMBV has emerged as the treatment of choice for severe pliable rheumatic mitral stenosis (MS). With increasing experience and better selection of patient, the immediate results of the procedure have improved and the rate of complications declined. When the reported complications of PMBV are viewed in aggregate, complications occur at approximately the following rates: mortality (0-0.5%), cerebral accident (0.5-1%), mitral regurgitation (MR) requiring surgery (1.6-3%). These complication rates compare favorably to those reported after surgical commissurotomy. Several randomized trials reported similar hemodynamic results with PMBV and surgical commissurotomy. Restenosis after PMBV ranges from 4 to 70% depending on the patient selection, valve morphology, and duration of follow up. Restenosis was encountered in 21% of the author's series at mean follow-up 6 +/- 4.5 years and the 10 and 15 years restenosis-free survival rates were (70 +/- 3)% and (44 +/- 5)%, respectively, and were significantly higher for patients with favorable mitral morphology (85 +/- 3% and 65 +/- 6%), respectively (P < 0.0001). The 10 and 15 years event-free survival rates were (79 +/- 2)% and (43 +/- 9)% and were significantly higher for patients with favorable mitral morphology (88 +/- 2)% and (66 +/- 6)%, respectively (P < 0.0001). The effect of PMBV on severe pulmonary hypertension, concomitant severe tricuspid regurgitation, left ventricular function, left atrial size, and atrial fibrillation are addressed in this review. In addition, the application of PMBV in specific clinical situations such as in children, during pregnancy and for restenosis is discussed.

show abstract

Section: Effect Of Pmbv On Left Atrial Sizementioning

confidence: 99%

Percutaneous mitral balloon valvotomy

Fawzy

2007

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…Significant reduction of LA size following successful mitral Valvotomy was demonstrated by several investigators (Takarada et al, 1992;Rittoo et al, 1993;Chen et al, 1992;Stefadouros et al, 1999). To demonstrate the effect of MBV on left atrial size, 205 consecutive patients (mean age 31 ± 11 years) were studied by the author (Stefadouros et al, 1999).…”

Section: Effect Of Mbv On Left Atrial Sizementioning

confidence: 87%

Mitral Balloon Valvuloplasty

1996

European Heart Journal

View full text Add to dashboard Cite

Percutaneous mitral balloon valvuloplasty (MBV) was introduced in 1984 by Inoue who developed the procedure as a logical extension of surgical closed commissurotomy. Since then, MBV has emerged as the treatment of choice for severe pliable rheumatic mitral stenosis (MS). With increasing experience and better selection of patient, the immediate results of the procedure have improved and the rate of complications declined. When the reported complications of MBV are viewed in aggregate, complications occur at approximately the following rates: mortality (0-0.5%), cerebral accident (1-2%), mitral regurgitation (MR) requiring surgery (1.6-3%). These complication rates compare favorably to those reported after surgical commissurotomy. Several randomized trials reported similar hemodynamic results with MBV and surgical commissurotomy. Restenosis after MBV ranges from 4% to 70% depending on the patient selection, valve morphology, and duration of follow-up. Restenosis was encountered in 31% of the author's series at mean follow-up 9 ± 5.2 years (range 1.5-19 years) and the 10, 15, and 19 years restenosis-free survival rates were (78 ± 2%) (52 ± 3%) and (26 ± 4%), respectively, and were significantly higher for patients with favorable mitral morphology (MES 6 8) at 88 ± 2%, 67 ± 4% and 40 ± 6%), respectively (P < 0.0001). The 10, 15, and 19 years event-free survival rates were (88 ± 2%, 60 ± 4% and 28 ± 7%, respectively, and were significantly higher for patients with favorable mitral morphology (92 ± 2%, 70 ± 4% and 42 ± 7%, respectively (P < 0.0001). The effect of MBV on severe pulmonary hypertension, concomitant severe tricuspid regurgitation, left ventricular function, left atrial size, and atrial fibrillation are addressed in this review. In addition, the application of MBV in specific clinical situations such as in children, during pregnancy and for restenosis is discussed.

show abstract

“…Significant reduction of LA size following successful mitral valvotomy was demonstrated by several investigators [38][39][40][41]. To demonstrate the effect of MBV on left atrial size 205 consecutive patients (mean age 31 ± 11 years) were studied by the author [41].…”

Section: Favorable Effect Of Mbv On Left Atrial Size and Atrial Fibrimentioning

confidence: 99%

Mitral Balloon Valvuloplasty: State-of-the-Art Paper

Fawzy

2006

CCR

View full text Add to dashboard Cite

Percutaneous mitral balloon valvuloplasty (MBV) was introduced in 1984 by Inoue who developed the procedure as a logical extension of surgical closed commissurotomy. Since then, MBV has emerged as the treatment of choice for severe pliable rheumatic mitral stenosis (MS). With increasing experience and better selection of patient, the immediate results of the procedure have improved and the rate of complications declined. When the reported complications of MBV are viewed in aggregate, complications occur at approximately the following rates: mortality (0% to 0.5%), cerebral accident (0.5% to 1%), mitral regurgitation (MR) requiring surgery (2% to 3%). These complication rates compare favorably to those reported after surgical commissurotomy. Several randomized trials reported similar hemodynamic results with MBV and surgical commissurotomy. Restenosis after MBV range from 4% to 70% depending on the patient selection, valve morphology and duration of follow up. Restenosis was encountered in 17.5% of the author's series and the 10-year restenosis free survival is 68% and is higher (78%) in patients with favorable mitral morphology. The 10-year event free survival is 80% and is higher (86%) in patients with favorable mitral morphology. The effect of MBV on severe pulmonary hypertension, concomitant severe tricuspid regurgitation, left ventricular function, left atrial size and atrial fibrillation will be addressed in the review. In addition, the application of MBV in specific clinical situations such as children, during pregnancy and for restenosis is discussed.

show abstract

Short- and Mid-Term Follow-Up Results after Percutaneous Transvenous Mitral Commissurotomy.

Cited by 5 publications

References 20 publications

Percutaneous mitral balloon valvotomy

Percutaneous mitral balloon valvotomy

Mitral Balloon Valvuloplasty

Mitral Balloon Valvuloplasty: State-of-the-Art Paper

Contact Info

Product

Resources

About